Page 177 - NobleCon20-Book-Project

Unicycive Therapeutics, Inc.

SELECTED FINANCIAL ITEMS UNCY

(in millions of USD)
CQ4 '23 CQ1 '24 CQ2 '24 CQ3 '24 LTM
Income Statement Key Items
Total Revenue 0.00 NA NA NA 0.00
Gross Profit 0.00 NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (6.31) (9.21) (7.40) (6.25) (29.17)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (7.80) (20.96) 9.86 (4.10) (23.00)
Net Margin NM NM NM NM NM

Balance Sheet Key Items
Total Assets 14.19 52.39 44.70 38.57 38.57
Cash & Short Term Investments 9.70 48.93 41.78 32.35 32.35
% of Assets 68% 93% 93% 84% 84%
Current Assets -Total 13.40 51.68 44.05 37.74 37.74
% of Assets 94% 99% 99% 98% 98%
Total Liabilities 18.00 30.65 13.36 10.72 10.72
% of Assets 127% 59% 30% 28% 28%
Current Liabilities - Total 17.53 30.28 13.09 10.46 10.46
% of Assets 124% 58% 29% 27% 27%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity (3.81) 21.73 31.34 27.85 27.85
% of Assets -27% 41% 70% 72% 72%

Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (4.44) (6.46) (6.32) (9.25) (26.47)
Net Cash Flow - Investing 0.00 (0.01) (0.02) (0.02) (0.05)
Net Cash Flow - Financing (0.21) 45.69 (0.81) (0.16) 44.52

Source: Capital IQ

PRICE / VOLUME

Source: Channelchek/QuoteMedia

Noble Capital Markets' Twentieth Annual Small & Microcap Investor Conference